Autopsy report · NCT06652841

Feasibility Study of the transShield Embolic Protection System

“Study Sponsor closing study due to financial circumstances.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 4 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

TransAortic Medical, Inc.

Sponsor type

Industry

Conditions

Aortic Stenosis

Interventions

transShield Embolic Protection System

Participants

2

Sites

1

Countries

New Zealand

Trials that died the same way

• Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
  “Study sponsor decided to close study.” (87% match in meaning)
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
  “Sponsor Decision to close study” (86% match in meaning)
• ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
  “Sponsor has decided to close study.” (85% match in meaning)
• L-Menthol Injection as a Novel Technique During Colonoscopy
  “Sponsor/Investigator has decided to close out the study” (80% match in meaning)
• Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
  “Study terminated due to closure of Sponsor business” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.